Teon Therapeutics: Teon Therapeutics is a private biopharma start-up developing a portfolio of small molecules that modulate metabolic signaling pathways in the tumor microenvironment. Teon's lead program is an A2BR-specific antagonist that is superior to other candidates like AB928 and AZD4635, and will enter Phase 1b trials in 2021. Our experienced leadership team are experts in adenosine and GPCR therapeutics and were primary inventors of Lexiscan and Ranexa, which led to the acquisition of CV Therapeutics by Gilead for $1.4B. We are currently raising a Series A that will help achieve multiple clinical milestones in the next 24 months.
Sector/Industry:
Healthcare/Biotechnology
Characteristics:
Based in...
US - Pacific
Clinical Stage
Pre-Clinical Stage
Disease Space
Oncology
Industry
Pharmaceuticals, Specialty Pharmaceutical
Listing
Private
Website:
Address:
555 Twin Dolphin Dr, Suite 120
Redwood City, CA 94065
United States

Upcoming Company Event Participation

Fall Private Company Showcase 2020

VIRTUAL, October 15, 2020